Is a New Era of SCLC, LCNEC Treatments on the Horizon?

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

Novel HER3 ADC Receives FDA Fast Track for Refractory NSCLC

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

DualityBio’s DB-1310 Gets FDA Fast Track For Lung Cancer

This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.